The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...

Over 11,000 liver transplants were performed last year in the US, while thousands more patients remained in limbo.

Approved targeted drugs for HER2 -mutant NSCLC include trastuzumab deruxtecan (T-DXd, Enhertu) -- which is highly effective ...

Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s ...

Shared biological, psychological, and social pathways put patients at risk for both, whether obesity or depression occurs ...

After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well ...

Collaboration and license agreement will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with a new asset expected to enter first-in-human studies next year.New, potentially ...

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...

Boehringer Ingelheim and AimedBio, a biotechnology company specializing in the development of antibody-based therapeutics, ...

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, hosted its CRM Summit on 10th–11th October at Conrad Abu Dhabi Etihad Towers.The event brought together more than 300 ...

According to Boehringer, Hernexeos achieved a 77% objective response rate (OOR) in a cohort of previously untreated HER2+ ...

Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were presented ...